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Backgound. The existence of a “placental clock” which determines the duration of gestation has been previously proposed. It is
related to placental CRH secretion and is active from an early phase in human pregnancy. Urocortin is a speciﬁc ligand for the
corticotropin-releasing factor (CRF) receptor expressed by human trophoblast and fetal membranes. The purpose of this study
was to evaluate whether urocortin concentrations in the early second trimester amniotic ﬂuid might serve to predict preterm
delivery. Method. The urocortin concentrations in early second trimester amniotic ﬂuid were measured in 41 pregnancies with
term delivery and in 41 pregnancies with preterm delivery by using an immunoradiometric assay. Conditional logistic regression
analysis was used for statistical analysis. Results. Mean amniotic ﬂuid urocortin concentrations in women with preterm labor
were 1.55 ± 0.63ng/mL while those in women with term labor were 1.6 ± 0.49ng/mL (p: NS). No statistical signiﬁcant results
were found when comparing amniotic ﬂuid urocortin concentrations in women with preterm premature rupture of membranes
leading to preterm labor (n = 19) to women with term delivery without premature rupture of membranes. Conclusion.T h e s e
results suggest that urocortin concentrations in the amniotic ﬂuid of genetic amniocentesis are not predictive of preterm labor and
birth.
Copyright © 2009 C. Iavazzo et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Preterm labor aﬀecting 10%–15% of all pregnancies [1]
is responsible for increased perinatal mortality and mor-
bidity, particularly for cerebral palsy [2]. Although various
obstetric, anatomic, or medical risk factors are associated
with preterm labor, 50% of such cases are idiopathic. An
inﬂammatory process was proposed by many authors. Thus,
increased amniotic ﬂuid levels of cytokines as IL-6, TNF-
α, IL1-ra, IL-8, ADAM-8, and ITAC [3–5] were determined
and were considered to serve as predictors of preterm labor.
However, other investigators suggest the “placental clock”
model in the prediction of labor onset [6]. Thus, it was
proposed that fetal or maternal stress might play a signiﬁcant
roleininitiatingthecascadeofintracellularsignalsleadingto
preterm labour [7].
Corticotropin releasing factor (CRF) family comprises
a variety of neuropeptides, CRF, and urocortin 1–3 [8].
Vaughan et al. [9] were the ﬁrst to identify urocortin—a
40-amino-acid peptide which exhibits a 45% homology to
CRF [10]—in the rat midbrain [9]. Urocortin is produced in
thesyncytiotrophoblast,deciduas,andfetalmembranes[11–
13]. Furthermore, Florio et al. stressed the important role of
the fetus as a source of urocortin during labour [14].
Urocortins act on CRF receptors [15, 16]. More speciﬁ-
cally, CRF-receptor-1 binds CRF and urocortin with similar
aﬃnity, whereas CRF-receptor-2 binds urocortin with a 40-
fold higher aﬃnity than CRF [16–18]. Both these neuropep-
tides bind to the receptors and act by activating G-protein-
coupled signal transduction and cAMP production [17, 18].
Urocortin is characterized by speciﬁc properties which
are implicated in the initiation of labor. Previous studies
described that urocortins could increase myometrial con-
tractility in an autocrine and paracrine manner through
CRF-receptors-2 [19–26]. They could act directly [22]
or indirectly through prostaglandins, estradiol, or ACTH2 Mediators of Inﬂammation
secretion [7, 11, 24, 27, 28] on the myometrial cells. Sirianni
et al. also pointed on the role of urocortin in trigger-
ing adrenal secretion of steroids relevant to parturition
[20]. Moreover, urocortin elevates MMP-9 levels which
lead to matrix disorganization and rupture of membranes
[26]. Also, they regulate placental blood ﬂow through
the NO/cGMP pathway [19, 23]. Furthermore, a role of
urocortin in the regulation of fetal adrenal function is
also proposed [25]. Taken into account the properties of
urocortin, we hypothesized that increased levels of amniotic
ﬂuid urocortin might predict, even from an early stage
of pregnancy, women prone to deliver at term. Therefore,
we aimed to determine urocortin levels in amniotic ﬂuid,
acquired during genetic amniocentesis, in women who
delivered preterm as compared to those delivering at term
and its possible inﬂuence on preterm premature rupture
of membranes. To our knowledge, this is the ﬁrst study to
examine this issue.
2. Method
A prospective cohort study was performed in collaboration
of the Second Department of Obstetrics and Gynecol-
ogy, University of Athens, Aretaieion Hospital, and the
Department of Fetal Medicine of “LITO” Maternity Hos-
pital, Athens, Greece, during the period September 2005–
December 2006. The study population consisted of Greek
womenwithsingletonpregnancieswhopresentedforgenetic
amniocentesis. Women with twin pregnancies and women
with known history of uterine abnormalities, cone biopsy,
signiﬁcant vaginal bleeding, and fetal malformations were
excluded from the study.
P r e t e r ml a b o rw a sd e ﬁ n e da sl a b o rb e f o r e3 7w e e k s
of gestation with regular uterine contractions (at least two
uterine contractions/10 minutes during 30 minutes) in
combination with the characteristic cervical changes [29–
32]. Preterm premature rupture of the fetal membranes
was deﬁned as the rupture of the amniotic membranes
with release of the amniotic ﬂuid more than one hour
before the onset of preterm labor (before 37 weeks of
gestation) [33]. Gestational age was calculated from the last
menstruation and was conﬁrmed during routine ultrasound
inthesecondtrimester(16–19weeksofgestation).Microbial
invasion of the amniotic ﬂuid was deﬁned in our study
as positive PCR for Mycoplasma hominis and Chlamy-
dia trachomatis and/or growth of any bacteria (aerobic
or anaerobic) in the amniotic ﬂuid cultures except for
coagulase-negative Staphylococcus, which was considered to
be a skin contamination. All patients were followed until
delivery for the occurrence of pregnancy complications.
An independent investigator kept the medical records and
entered maternal and perinatal data into a database. The
ethics committee of our teaching hospital approved the
study. Each woman gave informed consent before enrolment
in the study and completed a questionnaire including ques-
tions regarding personal data, personal history, and family
history.
Ultrasound-guided transabdominal amniocentesis with
a 21-gauge needle was performed under aseptic conditions
in 362 women during genetic amniocentesis. Amniocentesis
was performed for advanced maternal age and/or increased
risk for aneuploidy during nuchal translucency ultrasound.
The ﬁrst 0.5mL of amniotic ﬂuid was discarded to avoid
maternal contamination. Twenty mL of amniotic ﬂuid was
aspirated from each woman (15mL were used for genetic
diagnosis). One mL of the uncentrifuged amniotic ﬂuid
was then immediately transported to the microbiological
laboratory and was cultured for aerobic and anaerobic
bacteria. Another 1mL of the uncentrifuged amniotic
ﬂuid was also tested by polymerase chain reaction-PCR
for Mycoplasma hominis and/or Chlamydia trachomatis
detection. The remaining 3mL of amniotic ﬂuid were
immediately placed in a refridgerator (+4◦C) and were
centrifuged within the next 6 hours at 3000g and +4◦Cf o r
10 minutes. The supernatant was stored in polypropylene
tubes at −80
◦C until analysis in order to avoid urocortin
degradation.
Amniotic ﬂuid urocortin levels were determined with
anenzyme-linked immunosorbent assay(ELISA)(Urocortin
(human), EIA Phoenix Pharmaceuticals INC (Burlingame,
California, 94010)) which could measure urocortin in all
biological ﬂuids as long as its concentrations are above
the kits detection limit. The amniotic ﬂuid samples ran in
duplicates. The intra- and interassay coeﬃcients of variation
CV% were <5% and <14%, respectively. The detection limit
was 0.2ng/mL with a linear range 0.2–3.8ng/mL. It should
be mentioned that the urocortin (Human) EIA Kit (Catalog
No. EK-019-14) is speciﬁc for human Urocortin (100% cross
reactivity) and shows 0% cross reactivity with human CRF,
urocortin 2 or 3, and other substances (cortistatin 14, MCH,
LH-RH, NPY, or somatostatin-28) [34, 35]. Laboratory
personnel was blinded to the clinical history of the involved
women.
Women who gave a spontaneous preterm delivery were
deﬁned as cases (N=41) while, for each case, a woman
matched for age with normal pregnancy served as control
(N=41). Furthermore, subgroup analysis was conducted
in order to examine any possible association of urocortin
levels with the incidence of preterm delivery with premature
rupture of membranes. Nineteen women with preterm labor
and premature rupture of membranes were deﬁned as cases,
while for every case a woman matched for maternal age
delivering at term served as control (N1=19). Cases and
controls delivered either spontaneously or by caesarean
section.
All data except for age, gestational age at delivery, and
gestational age at amniocentesis followed normal distri-
bution (Kolmogorov-Smirnov test). Independent samples
t-test was applied to detect diﬀerences between groups
where continuous variables were normally distributed (uro-
cortin and birthweight). Otherwise, Mann–Whitney U-
test was applied. Pearson’s Chi square test was used to
detect diﬀerences between categorical variables. Condi-
tional logistic regression analysis was used to examine
the possible associations of urocortin with preterm labor.
STATA 8.2 and SPSS 11.5 edition were used for the anal-
ysis. A P-value of <.05 was considered to be statistically
signiﬁcant.Mediators of Inﬂammation 3
3. Results
Out of 362 pregnant women who were included in the study,
41 had preterm labor (incidence: 11.26%) and a subgroup
of 19 women delivered preterm with premature rupture
of membranes (incidence: 5.22%). Ten were excluded after
amniocentesis in the presence of fetal chromosomal abnor-
malities (two with trisomy 18, two with trisomy 21, one with
Turner syndrome, one with Klinefelter syndrome, and other
four with less usual karyotypes). Eight women were lost to
follow-up. Four infants were delivered by caesarean section
before the onset of labor for maternal (severe preeclampsia)
or fetal reasons (compromised fetal growth or umbilical
Doppler ﬂow abnormalities). Two women delivered within
30 days following amniocentesis and were excluded from
the study, as their delivery was considered related to the
procedure of amniocentesis [36–40].
The demographic data of the study population are
presented in Tables 1 and 2. No statistical signiﬁcant
diﬀerences concerning mean maternal age, gestational age at
amniotic ﬂuid sampling, indication for amniocentesis, and
incidence of nulliparity were shown between the groups.
Amniotic ﬂuid cultures for common bacteria were negative,
whileMycoplasmahominisandChlamydiawereidentiﬁedin
2/338 and 2/338 subjects, respectively. However, one of the
two women with Mycoplasma and one of the two women
with Chlamydia delivered preterm.
Logistic regression analysis did not show any signiﬁcant
associations between urocortin levels and preterm delivery.
Furthermore, no signiﬁcant association between urocortin
concentrations and the time interval between amniotic ﬂuid
sampling and delivery was observed. More speciﬁcally, the
amniotic ﬂuid levels of urocortin in women with preterm
labor were not signiﬁcantly higher than in women delivering
at term (1.55 ± 0.63ng/mL versus 1.52 ± 0.43ng/mL)
(Figure 1(a)).Moreover,nosigniﬁcantassociationwasfound
between urocortin levels and preterm delivery with prema-
ture rupture of membranes. More speciﬁcally the amniotic
ﬂuid levels of urocortin in women with premature rupture
of membranes were not higher than in women at term (1.64
± 0.54ng/mL versus 1.6 ± 0.49 ng/mL (Figure 1(b)).
4. Discussion
Thisistheﬁrststudywhichexaminedanassociationbetween
amniotic ﬂuid urocortin levels and possible prediction of
preterm labor among asymptomatic women during the
second trimester of pregnancy. The gene expression and
localization of urocortin in syncytiotrophoblast, cytotro-
phoblast, and deciduas by using in situ hybridization and
immunohistochemistry were reported in a study [11]. Also,
other investigators showed that immunoreactive urocortin
was detectable in maternal plasma from seven weeks of
gestation and that such concentrations did not change as
gestation progressed [41]. In another study, it was found
that fetal plasma urocortin levels measured in umbilical
cord artery and vein were increased in term and preterm
labors [42]. Moreover, in the same study, it was revealed
that maternal and fetal plasma urocortin levels increase
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Figure 1: (a) Error bars of the concentrations of amniotic ﬂuid
urocortin from women with preterm delivery (cases) (Mean ±
SD: 1.55 ± 0.63ng/mL) and fullterm delivery (controls) (Mean ±
SD:1.52 ± 0.43ng/mL). Each box represents the mean (95% CI)
concentration. (b) Error bars of the concentrations of amniotic
ﬂuid urocortin from women with preterm delivery and premature
rupture of membranes (cases) (Mean ± SD:1.64 ± 0.54ng/mL)
and women with fullterm delivery (controls) (Mean ± SD: 1.6 ±
0.49ng/mL). Each box represents the mean (95% CI) concentra-
tion.
at term or preterm vaginal labor compared to those after
elective caesarean section [42]. It is known that the levels
of CRF in maternal plasma increase throughout pregnancy,
whereasurocortin remains constant [41, 43]. For this reason,
many investigators proposed that urocortin might play an
important role in human parturition and onset of labor
[42, 44].
It has been stated that CRH and urocortin 1 appear to
be predictors of the duration of gestation [27]. This could be
explained by the fact that CRH through its receptors protects
gestation by promoting myometrial quiescence via the4 Mediators of Inﬂammation
Table 1: Demographic data of women with preterm (N=41) and term delivery (N=41).
Groups
Preterm delivery
(N=41) Mean ±
SD/Median
(Range)
Controls (N=41)
Mean ±
SD/Median
(Range)
P value
Gestational age at delivery (weeks) 35.5 (22–37.6) 38.4 (37–40) <.001
Gestational age at amniocentesis
(weeks) 17.9 (15.1–25.4) 17.4 (15.9–23.7) NS
Birth weight (g) 2469.7 ± 582.6 3172 ± 378 <.001
Age (years) 37 (27–43) 37 (27–44) NS
<35 N (%) 15 (36.6) 13 (31.7) —
>=35 N (%) 26 (63.4) 28 (68.3) —
Parity — — NS
First N (%) 16 (39) 15 (36.6) —
Other N (%) 25 (61) 26 (63.4) —
Smoking before pregnancy N (%) 16 (39) 15 (36.6) NS
Smoking during pregnancy N (%) 8 (19.5) 9 (22) NS
Alcohol Consumption before preg-
nancy N (%) 5 (12.2) 11 (26.8) NS
Alcohol Consumption during preg-
nancy N (%) 1 (2.4) 3 (7.3) NS
Use of drugs 13 (31.7) 18 (43.9) NS
Table 2: Demographic data of women with preterm labor and premature rupture of membranes (N=19) and women delivering at term
(N=19).
Groups
Preterm delivery with
premature rupture of
membranes (N=19)
Mean ± SD/Median
(Range)
Controls (N=19)
Mean ±
SD/Median
(Range)
P value
Gestational age at delivery (weeks) 36 (22–37.6) 38.6 (37.3–39.9) <.001
Gestational age at amniocentesis
(weeks) 17.9 (15.6–25.4) 17.4 (15.9–23.7) NS
Birth weight (g) 2508.3 ± 657.7 3234.2 ± 416.3 <.001
Age (years) 37 (27–43) 37 (29–44) NS
<35 N (%) 5 (26.3) 6 (31.6) —
>=35 N (%) 14 (73.7) 13 (68.4) —
Parity — — NS
First N (%) 9 (47.4) 7 (36.8) —
Other N (%) 10 (52.6) 12 (63.2) —
Smoking before pregnancy N (%) 7 (36.8) 6 (31.6) NS
Smoking during pregnancy N (%) 4 (21.1) 2 (10.5) NS
Alcohol Consumption before preg-
nancy N (%) 4 (21.1) 7 (36.8) NS
Alcohol Consumption during preg-
nancy N (%) 1 (5.3) 1 (5.3) NS
Use of drugs 4 (21.1) 7 (36.8) NS
generation of cAMP and cGMP and by upregulating nitric
oxide synthase expression [14]. As proposed, urocortin has a
signiﬁcant role in uterine contractility in vitro by indirectly
triggering a myometrial response through stimulation of
placental adrenocorticotropin and prostaglandin release [7,
27]. Some investigators showed a distinctive role of CRF-
receptors-2 in the control of uterine contractility during
pregnancy [28]. Moreover, they suggested that urocortin
2 could have a dual role during pregnancy and labor:
ﬁrstly, in the maintenance of myometrial relaxation andMediators of Inﬂammation 5
secondly, in the stimulation of contractility [28]. Other
investigators trying to explain the possible mechanisms of
myometrial stimulation found that CRH-induced activation
is insuﬃcient [21]. On the other hand, urocortin 1 could
act through its receptors and could stimulate myometrial
mitogen-activated protein kinase in cultured human preg-
nant myometrial cells [21].
In explaining preterm labor, the mechanism of
the urocortin-activated placental, maternal, and fetal
hypothalamo-pituitary-adrenal axis, as a response to
stress, has been also implicated [20]. In this respect,
urocortin has been used to test this theory. Thus, it
has been proposed that ACTH, CRH, and urocortin 1
stimulate the fetal adrenal near term by increasing the
production of cortisol and dehydroepiandrosterone sulfate
and by activating CRF-receptor-1 [20]. The elevation in
dehydroepiandrosterone sulfate levels could be used for
placental estrogen synthesis, a fact that leads to parturition
in humans [20]. At term, uterine contractility is proposed to
be enhanced by upregulation of oxytocin receptor expression
and communication between oxytocin and CRH receptors
[21]. CRH/urocortins have a dual role: on the one hand
by acting via their receptors and on the other by activating
G-protein-coupled signal transduction and potentially
by enhancing the oxytocin-driven generation of inositol
triphosphate [19, 21–25]. Moreover, they generate—via
their receptors—prostaglandins from the fetal membranes
and deciduas; they play a role in placental vasodilation
and they participate in fetal adrenal function and organ
maturation in order to protect the fetus from environmental
stress [19, 21–25]. Urocortin was also shown to induce a
degradation of extracellular matrix by secretion of matrix-
metalloproteinase-9 (MMP-9) with no changes in tissue
inhibitors of MMP-1 (TIMP-1), a process leading to rupture
of membranes [26].
Recent studies used maternal plasma urocortin between
28 and 34 weeks gestation to predict preterm delivery in
women with threatened preterm labor [45]. They found that
plasma urocortin was signiﬁcantly higher in women who
delivered preterm versus those delivering at term [45]. Based
on the above ﬁndings, we investigated whether amniotic
ﬂuid urocortin levels during genetic amniocentesis could
serve as a new marker predicting preterm labor. However,
no statistically signiﬁcant association was found neither in
the group of preterm labor nor in the group of premature
r u p t u r eo fm e m b r a n e sg r o u pw h e nc o m p a r e dw i t hg r o u po f
women delivering at term. In contrast to Florio et al. [45],
we studied amniotic ﬂuid urocortin levels at an earlier time
point (second trimester) and in a diﬀerent ﬂuid (amniotic
ﬂuid versus maternal plasma). Furthermore, patients in the
abovementioned study presented a threatened labor. It is
noteworthythatourpretermdeliveryrateof11.3%occurred
in a general and nonhigh-risk obstetric population who
underwent amniocentesis for elevated maternal age or high
nuchal translucency. Although our study did not ﬁnd a
predictive role of urocortin, the elevation of its levels with
advancing gestation cannot be excluded. In conclusion, the
present study did not ﬁnd an association between urocortin
levels in the second trimester and preterm delivery. Further
studies are needed to elucidate the possible role of urocortin
in human parturition.
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